Financial Performance - The company expects a net loss attributable to shareholders for the first half of 2024 to be between -13 million and -16 million CNY, with a net loss excluding non-recurring gains and losses estimated between -16 million and -19 million CNY[5]. - The earnings per share for the first half of 2023 was -0.0232 CNY[7]. - The net profit attributable to shareholders for the current period is reported at -11.1553 million CNY, with a net profit excluding non-recurring gains and losses at -16.9464 million CNY[15]. Business Development - The rehabilitation medical division and nursing facilities are still in the development phase and have not yet turned profitable[8]. - Revenue and profit from the aquatic products division have declined due to a sluggish market for soft-shelled turtles[8]. Government Support - Government subsidies have significantly decreased compared to the same period last year[9]. Financial Reporting - The preliminary financial data is subject to final confirmation in the official half-year report[10]. - The company has communicated with the auditing firm regarding the earnings forecast, indicating no major uncertainties affecting the accuracy of the forecast[9]. - The expected net profit for the first half of 2024 falls under the category of negative net profit, necessitating the disclosure of an earnings forecast[13].

尊敬的各位投资者大家好我是大股份总统秘书杨波骄阳六月 热情洋溢感谢大家参加大股份2023年业绩说明会 本次业绩透明会采用网络视频加文字互动的形式与大家进行交流在此先向大家介绍今天出席业绩透明会的嘉宾现场出席的嘉宾有公司董事长罗定庚先生副董事长孙永志先生 董事郭自强先生财务总监戴金华女士两位独立董事刘继光先生王冰女士远程参加业绩说明会今天的业绩说明会将有分为五个环节 第一个环节是由公司董事长罗宁坤先生致辞并汇报公司2023年的经营情况第二个环节由公司财务总监戴琛华女士汇报2023年的业绩情况及主要财务指标第三个环节由公司董事郭富城先生汇报公司2023年社会责任履行情况 第四个环节由公司副董事长孙永智先生汇报2023年的发展规划第五个环节是针对投资者关心的问题与广大投资者进行网络文字互动接下来进行会议的第一个环节有请公司董事长罗立军先生致辞并汇报公司2023年的经济情况 各位投资者大家好我是大蜘蛛共同生长罗定奎很高兴能就公司2023年的经营情况和大家进行沟通交流在此我代表公司向历史以来关心、关注和支持公司发展的各位股东、各位投资者表示衷心的感谢向参加此次建议说明会的各位投资者和各位朋友表示热烈的欢迎 感谢上海金融 ...

Summary of the Conference Call Company Overview - The conference call is regarding "大股份" (Da Holdings) and its 2023 performance briefing [1] Key Points and Arguments - The president's secretary, Yang Bo, expressed gratitude to investors for attending the performance briefing [1] Other Important Content - The call took place in June, indicating a mid-year review of the company's performance [1]

关于召开 2023 年年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示 ●会议召开时间：2024 年 06 月 07 日(星期五)下午 15:00-16:30 ●会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） ●会议召开方式：上证路演中心视频和网络互动 ●投资者可于 2024 年 05 月 31 日(星期五)至 06 月 06 日(星期 四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通 过 大 湖 水 殖 股 份 有 限 公 司 （ 以 下 简 称 " 公 司 " ） 邮 箱 dmbgs@dhszgf.com 进行提问。公司将在说明会上对投资者普遍关注 的问题进行回答。 公司已于 2024 年 4 月 18 日披露公司 2023 年年度报告，为便于 广大投资者更全面深入地了解公司 2023 年度经营成果、财务状况， 公司计划于 2024 年 06 月 07 日下午 15:00-16:30 举行 2023 年 ...

湖南启元律师事务所 关于大湖水殖股份有限公司 2023年年度股东大会的 法律意见书 二零二四年五月八日 致：大湖水殖股份有限公司 湖南启元律师事务所接受大湖水殖股份有限公司（以下简称"公司"）的委托， 指派本所律师出席了公司 2023 年年度股东大会（以下简称"本次股东大会"）， 对会议进行现场律师见证，并出具本法律意见书。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》 等法律、法规和规范性文件以及《大湖水殖股份有限公司章程》（以下简称"《公 司章程》"）的有关规定，出具本法律意见书。 为出具本法律意见书，我们依法审核了公司提供的下列资料： 1、刊登在上海证券交易所网站（http://www.sse.com.cn/）上的《第九届董事 会第八次会议决议公告》（以下简称"《董事会决议》"）及《关于召开 2023 年 年度股东大会的通知》（以下简称"《股东大会通知》"）； 2、出席会议股东或其代理人的资格、身份证明文件等； 3、公司本次股东大会股权登记日的股东名册、出席现场会议的股东的到会 签到册等资料； 4、公司本次 ...

证券代码：600257 证券简称：大湖股份 公告编号：2024-017 大湖水殖股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2024 年 5 月 8 日 (二)股东大会召开的地点：湖南省常德市武陵区建设东路 348 号泓鑫桃林 6 号楼 21 楼会议室。 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 169 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 109,818,289 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 22.8199 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由董事会召集，会议召集与召开程序符合《公司法》及《公司章程》 的相关规定，合法有效。会议由董事长罗订坤先生主 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 208,442,460.81, representing a decrease of 16.65% compared to the same period last year[4]. - Total operating revenue for Q1 2024 was CNY 208.44 million, a decrease of 16.7% compared to CNY 250.09 million in Q1 2023[17]. - The net profit attributable to shareholders was a loss of CNY 7,910,466.66, an increase in loss of 13.43% year-over-year[4]. - Net profit for Q1 2024 was a loss of CNY 2.92 million, an improvement from a loss of CNY 7.24 million in Q1 2023[18]. - The company reported a total comprehensive loss of CNY 3.03 million in Q1 2024, compared to a loss of CNY 8.13 million in Q1 2023[18]. - Basic and diluted earnings per share were both CNY -0.016, reflecting a 15.79% increase in loss compared to the previous year[4]. - Basic and diluted earnings per share for Q1 2024 were both CNY -0.016, compared to CNY -0.019 in Q1 2023[18]. Cash Flow - The net cash flow from operating activities was negative at CNY 24,356,734.57, with no applicable percentage change due to the nature of the data[4]. - Cash flow from operating activities for Q1 2024 was negative CNY 24.36 million, a decline from positive CNY 9.71 million in Q1 2023[21]. - Cash inflow from operating activities totaled CNY 232.57 million in Q1 2024, down from CNY 308.01 million in Q1 2023[21]. - Cash outflow from operating activities was CNY 256.92 million in Q1 2024, compared to CNY 298.30 million in Q1 2023[21]. - The net cash flow from investing activities was -$46,394,560.63, compared to -$7,300,148.05 in the previous period, indicating a significant increase in cash outflow for investments[23]. - The company reported a significant increase in cash outflow for investments, with total cash outflow reaching $73,458,850.63 compared to $7,408,148.05 previously[23]. - The company’s cash and cash equivalents decreased by $86,751,678.58 during the quarter, contrasting with an increase of $13,758,411.71 in the previous period[23]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,029,269,487.95, down 2.33% from the end of the previous year[5]. - The company's current assets totaled RMB 927,601,251.71, down from RMB 954,499,301.96, indicating a decrease of about 2.8%[12]. - The total liabilities as of the end of Q1 2024 were CNY 1,014.53 million, a decrease from CNY 1,059.83 million at the end of Q1 2023[13]. - The equity attributable to shareholders decreased by 0.92% to CNY 868,136,757.92 compared to the end of the previous year[5]. - Cash and cash equivalents decreased to RMB 249,420,102.19 from RMB 336,171,780.77, representing a significant decline of approximately 26%[12]. - Accounts receivable increased to RMB 103,183,968.45 from RMB 97,821,503.55, showing an increase of about 5.5%[12]. - Inventory rose to RMB 465,166,071.79 from RMB 455,021,341.59, marking an increase of approximately 2.2%[12]. - Short-term borrowings decreased to RMB 249,787,720.08 from RMB 258,826,333.32, reflecting a reduction of about 3.8%[12]. - Accounts payable decreased to RMB 36,547,406.22 from RMB 54,183,533.62, indicating a decline of approximately 32.5%[12]. Other Financial Information - Non-recurring gains and losses amounted to CNY 2,089,748.78, with significant contributions from government subsidies and asset disposals[7]. - The company reported a 236.12% increase in trading financial assets, primarily due to an increase in structured deposits[7]. - Deferred income increased by 40.74%, mainly due to government subsidies received[7]. - The company reported a total of 104,631,211 shares held by its largest shareholder, Tibet Hongshan Technology Development Co., Ltd.[10]. - The company has not reported any changes in the participation of major shareholders in securities lending activities[11]. - The company has not identified any significant related party transactions among its top shareholders[10]. - The company has not adopted new accounting standards or interpretations for the current year[23].

大湖水殖股份有限公司 审 计 报 告 众环审字 (2024) 1100028 号 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://scc.mof.gov.cn）"进行查账 报告编码:鄂24Q9UG i 审计报告 众环审字(2024)1100028 号 大湖水殖股份有限公司全体股东: 一、审计意见 我们审计了大湖水殖股份有限公司(以下简称"贵公司"或者"大湖股份")财务报表, 包括 2023 年 12 月 31 日的合并及公司资产负债表,2023 年度的合并及公司利润表、合并及 公司现金流量表、合并及公司股东权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了 贵公司 2023 年 12月 31 日合并及公司的财务状况以及 2023 年度合并及公司的经营成果和现 金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会计师对 财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照中国注册会计师职 业道德守则,我们独立于贵公司,并履行了职业道德方面的其他责任。我们相信,我们获 ...

Financial Performance - The net profit attributable to the parent company for 2023 was negative, resulting in distributable profits below 5 million RMB, thus no profit distribution or capital reserve transfer will occur this year[5]. - The company achieved operating revenue of CNY 1,193,454,619.46, representing a year-on-year increase of 9.02%[117]. - The company's net profit attributable to shareholders was a loss of CNY 815,870[117]. - The total assets of the company as of December 31, 2023, amounted to CNY 207,759,790[117]. - The operating cost increased by 7.81% year-on-year, totaling CNY 900,664,999.93[117]. - The company reported a net cash flow from operating activities of CNY 162,089,223.95, a significant increase of 65.62% compared to the previous year[117]. - The company’s main product revenue from agriculture was CNY 627,113,773.53, with a gross margin of 13.28%[121]. - The company’s main product revenue from industrial operations was CNY 142,911,394.16, with a gross margin of 61.27%[121]. - The company reported a total revenue of 1,136,393,469.59 CNY from offline sales, with a year-on-year increase of 7.13%[127]. - Online sales revenue reached 43,881,449.35 CNY, showing a significant year-on-year growth of 79.48%[127]. Operational Risks and Governance - The company has faced various operational risks, including market competition, food safety, and cost fluctuations, which are detailed in the management discussion section[11]. - The company has established a comprehensive internal control system, with clear responsibilities and risk identification procedures in place[173]. - The company is focused on enhancing internal controls and management quality to support its expansion into the medical services industry[173]. - The company aims to mitigate risks through refined management and brand premium enhancement strategies[172]. - The company plans to strengthen risk control and ensure stable production operations by improving internal controls across various aspects including product safety and supply chain management[190]. - The board of directors has confirmed that all members attended the board meeting, ensuring the integrity of the report[4]. - The board of directors consists of 5 members, including 2 independent directors, complying with legal requirements[176]. - The supervisory board has 3 members, ensuring oversight of the company's operations and financial situation[178]. - The company held 7 supervisory board meetings during the reporting period, demonstrating active governance[178]. - The company held one annual general meeting and four extraordinary general meetings during the reporting period, ensuring equal rights for all shareholders[197]. Business Strategy and Development - The company aims to enhance its internal control system and improve corporate governance to mitigate operational risks and promote high-quality and stable development[53]. - The company is committed to building a comprehensive health industry chain, integrating liquor production and sales with health medical services[54]. - The company aims to upgrade its health product offerings and medical services, aligning with the growing health industry trends[70]. - The company is focusing on the healthcare service sector with a long-term plan to establish a chain of high-quality medical services, starting from Shanghai and expanding nationwide[191]. - The company is committed to optimizing its aquaculture and deep processing industry chain, leveraging high-quality water resources for sustainable development[155]. - The company is enhancing its training programs for medical personnel to improve service levels and ensure sustainable development in its healthcare facilities[79]. - The company aims to improve its governance system and management efficiency to better support business development, focusing on the strategy of "health products + health medical services"[79]. Market and Product Development - The company is enhancing its product structure and marketing network to solidify its aquaculture business and improve the quality and safety of frozen seafood products[62]. - The company is expanding its marketing channels to increase market share, particularly in the white liquor segment, which is experiencing steady sales growth[67]. - The company launched several new products in 2023, including Yellow Braised Soft-Shelled Turtle and Spicy Boiled Fish, to meet diverse consumer demands[77]. - The company is leveraging both online and offline sales channels, partnering with major retailers and e-commerce platforms to enhance market penetration[78]. - The company is committed to ecological aquaculture practices, ensuring the production of high-quality organic freshwater products[76]. - The white liquor segment is focusing on quality and market-driven production, maintaining a competitive edge with its product offerings[78]. - The company recognizes the competitive advantage of its natural fish products over pond-raised fish, emphasizing quality and health benefits as consumer demand for green food increases[194]. - The rise of prepared seafood dishes represents a new growth point for the aquatic product industry, driven by changing consumer habits and increased demand for convenience[84]. - The company has received various certifications for its aquatic products, including organic product certification and "pollution-free agricultural product" certification, enhancing its market competitiveness[95]. Financial Transactions and Investments - The company transferred 100% equity of its wholly-owned subsidiary, Dehai Medical Trade, to Hunan Dehai Pharmaceutical Co., Ltd. for a transaction price of RMB 29.8 million, with an appraisal value increase of RMB 4.9463 million, representing a 19.90% appreciation rate[39]. - The company signed a debt-to-equity agreement on June 7, 2023, converting a debt of RMB 9 million into equity for Hangzhou Dongfang Huakang, increasing its ownership from 70% to 72%[58]. - The company transferred its wholly-owned subsidiary, Hunan Dehai Pharmaceutical Trading Co., Ltd., in June 2023, optimizing its business structure[124]. - The company has converted a debt of ¥40 million into equity for Wuxi Rehabilitation Hospital, increasing its registered capital from ¥10 million to ¥50 million[150]. Customer and Supplier Relations - The top five customers contributed CNY 313,435,781.87, accounting for 26.26% of the total operating revenue[124]. - The top five suppliers accounted for CNY 19,803,230, representing 31.65% of the total annual procurement[125]. - The company’s reliance on a single supplier exceeded 50% of total purchases, indicating a significant dependency risk[126]. - The top five customers accounted for 26.26% of total annual sales, with no sales to related parties[140]. Research and Development - Research and development expenses totaled 961,780.17 CNY, representing 0.08% of total revenue[136].

大湖水殖股份有限公司 关于 2023 年度会计师事务所履职情况评估报告 大湖水殖股份有限公司（以下简称"公司"）聘请中审众环会计 师事务所（特殊普通合伙）（以下简称"中审众环"）作为公司 2023 年度财务报告及内部控制审计的会计师事务所。根据《中华人民共和 国公司法》《中华人民共和国证券法》《上市公司治理准则》《国有企 业、上市公司选聘会计师事务所管理办法》《上海证券交易所上市公 司自律监管指引第 1 号——规范运作》等法律法规的要求，公司董事 会对中审众环会计师事务所在 2023 年度审计工作的履职情况进行了 评估，具体情况如下： 一、2023 年年审会计师事务所基本情况 2022 年度经审计的收入总额 213,165.06 万元、审计业务收入 181,343.80 万元，证券业务收入 57,267.54 万元。 2022 年度上市公司审计客户家数 195 家，涉及的主要行业包括 制造业，批发和零售业，房地产业，电力、热力、燃气及水生产和供 应业，农、林、牧、渔业，信息传输、软件和信息技术服务业，采矿 业，文化、体育和娱乐业等，审计收费 24,541.58 万元。2023 年审 计农、林、牧、渔业同行业上 ...